evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,125 questions · 1,173 findings · 91 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 192 · 16.4%GRADE not reported 47 · 4%Very low 199 · 17%Low 325 · 27.7%Moderate 271 · 23.1%High 139 · 11.8%

Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone

Mortality Median · patients with primary CNS lymphoma

Cytarabine plus high‐dose methotrexate showed no clear difference in mortality (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).

1 finding from 1 review

Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone

Progression/relapse · patients with primary CNS lymphoma

Cytarabine plus high‐dose methotrexate probably leads to lower progression/relapse (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).

1 finding from 1 review

Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone

Treatment‐related mortality · patients with primary CNS lymphoma

Cytarabine plus high‐dose methotrexate showed no clear difference in treatment‐related mortality compared with high‐dose methotrexate alone (moderate certainty).

1 finding from 1 review

Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone

Severe adverse effects (grade 3+): Infection · patients with primary CNS lymphoma

Cytarabine plus high‐dose methotrexate probably leads to higher infections (grade 3 to 4) compared with high‐dose methotrexate alone (moderate certainty).

1 finding from 1 review